Bonomo Lauren, Levitt Jacob O
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Cutis. 2018 May;101(5):367-369.
Refractory pityriasis rubra pilaris (PRP) often is treated off-label with the same biologic therapies that are approved for the treatment of psoriasis, most commonly tumor necrosis factor (TNF) α antagonists and ustekinumab; however, the IL-17A antagonist secukinumab also has shown efficacy in the treatment of PRP. We report 2 new cases of severe refractory PRP that responded rapidly to treatment with secukinumab.
难治性毛发红糠疹（PRP）通常采用治疗银屑病获批的相同生物疗法进行超说明书用药治疗，最常用的是肿瘤坏死因子（TNF）α拮抗剂和乌司奴单抗；然而，白细胞介素-17A拮抗剂司库奇尤单抗在PRP治疗中也显示出疗效。我们报告2例严重难治性PRP新病例，其对司库奇尤单抗治疗反应迅速。
